ASCO GU 2026: Updates in metastatic prostate cancer
Dr Chowdhury talks to ecancertv at ESMO 2016 about the Cancer Registry, that monitors the treatments and outcomes of over 3,000 patients across Europe with metastatic castration-resistant prostate cancer (mCRPC).
Dr Chowdhury also spoke with ecancer about fatigue among mCRPC patients treated with enzalutamide here.
ASCO GU 2026: Updates in metastatic prostate cancer
Prostate cancer
ESMO 2024: Highlights and analysis
OncoAlert Round Up for September 15-21, 2023
OncoAlert Round Up for August 25th - 31st, 2023
War in Ukraine: The Global Medical Knowledge Alliance's response to improving cancer care
Latest in immunological technologies that can treat, control, and prevent cancer
Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
Neo-adjuvant therapy for different cancers in the Philippines